Site-Agnostic Cancer Drugs: HTAs Will Need Post-Approval Data
Early Scientific Advice From HTA Bodies Also Recommended
Executive Summary
With histology-independent cancer drugs such as Vitrakvi coming to market, a new paper explores how to address the challenges in assessing the clinical and cost effectiveness of these new types of treatments.
You may also be interested in...
Roche Wins Funding For Second Histology-Independent Drug In England
Patients in England with NTRK fusion-positive solid tumors will now have access to another cutting-edge cancer treatment that can be used to treat tumors regardless of where in the body they originated.
Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection
Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.